
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems is experiencing short-term challenges with coding uncertainty and prior authorization delays, leading to lower guidance for revenue and EPS in 2026. However, the company is expected to return to revenue growth in 2027 and its long-term potential is supported by a new product cycle and underpenetrated TAM. Due to the current uncertainties and lack of visibility, we have a neutral rating on the stock.
Bears say
Inspire Medical Systems is facing significant headwinds in the near future due to uncertainty surrounding reimbursement coding and the WISeR program. This has led to a decrease in revenue growth guidance and a decline in the company's stock price. Additionally, the launch of the next-gen Inspire V device may not be enough to offset these challenges and return the company to positive growth in the near term. Investors should monitor the company's progress in addressing these issues before making any investment decisions.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares